Table 1.
Relationship of CD44 and ALDH1/2 Expression with Clinicopathologic Parameters
| CD44 expression36/80 (45.0%) | ALDH1/2 expression54/80 (67.5%) | Co-expression 25/80 (31.25%) | |||||
|---|---|---|---|---|---|---|---|
| Characteristics | Total number | Positivite rate | P-Value | Positivite rate | P-Value | Positivite rat | P-Value |
| Sex | |||||||
| *Male | 48 | 24/48(66.7%) | 0.36 | 34/48 (63.0%) | 0.47 | 41/48 (63.1%) | 0.381 |
| *Female | 32 | 12/32(33.3%) | 20/32 (37.0%) | 24/32 (36.9%) | |||
| Histology | |||||||
| *intestinal | 58 | 28/58(77.8%) | 0.115 | 40/58 (74.1%) | 0.93 | 48/58 (73.8%) | 0.635 |
| *diffuse | 14 | 3/14 (8.3%) | 9/14 (16.7%) | 10/14 (15.4%) | |||
| *mixed | 8 | 5/8 (13.9%) | 5/8 (9.3%) | 7/8 (10.8%) | |||
| Differentiation | |||||||
| *well | 9 | 3/9 (8.3%) | 0.335 | 6/9 (11.1%) | 1.000 | 6/9 (9.2%) | 1.190 |
| *moderate | 37 | 20/37(55.6%) | 25/37 (46.3%) | 33/37 (50.8%) | |||
| *poorly | 34 | 13/34(36.1%) | 23/34 (42.6%) | 26/34 (40.0%) | |||
| Lymphatic invasion | |||||||
| *Yes | 66 | 31/66(86.1%) | 0.559 | 45/66 (83.3%) | 1.000 | 55/66 (84.6%) | 0.450 |
| Perineural invasion | |||||||
| *Yes | 56 | 24/56(66.7%) | 0.628 | 38/56 (70.4%) | 1.000 | 46/56 (70.8%) | 1.000 |
| Lymph node metastasis | |||||||
| *Yes | 66 | 31/66(86.1%) | 0.559 | 45/66 (83.3%) | 1.000 | 55/66 (84.6%) | 0.450 |
| Tumor location | |||||||
| *proximal | 28 | 12/28(33.7%) | 0.817 | 17/28 (31.5%) | 0.4 | 21/28 (32.3%) | 0.370 |
| *distally | 52 | 24/52(66.7%) | 37/52 (68.5%) | 44/52 (67.7%) | |||
| Depth of invasion | |||||||
| *mucosa | 4 | 1/4 (2.8%) | 0.795 | 1/4 (1.9%) | 0.22 | 1/4 (1.5%) | |
| *muscularis propria | 8 | 4/8 (11.1%) | 6/8 (11.1%) | 7/8 (10.8%) | |||
| *serosa | 68 | 31/68(86.1%) | 47/68 (87.0%) | 57/68 (87.7%) | 0.028* | ||
| TNM Stage | |||||||
| *I | 6 | 2/6 (33.3%) | 0.507 | 2/6 (33.3%) | 0.19 | 1/6 (16.6%) | 0.714 |
| *II | 15 | 5/15 (33.3%) | 10/15 (66.7%) | 4/15 (26.6%) | |||
| *III | 59 | 29/59(49.2%) | 42/59 (71.2%) | 20/59 (33.9%) | |||
*
X2 test, p<0.05 was considered significant; Tumor stage was classified according to the American Joint Committee on Cancer (AJCC) TNM staging system; ALDH1/2: aldehyde dehydrogenase ½.